SG11201501634VA - Nootropic compositions for improving memory performance - Google Patents
Nootropic compositions for improving memory performanceInfo
- Publication number
- SG11201501634VA SG11201501634VA SG11201501634VA SG11201501634VA SG11201501634VA SG 11201501634V A SG11201501634V A SG 11201501634VA SG 11201501634V A SG11201501634V A SG 11201501634VA SG 11201501634V A SG11201501634V A SG 11201501634VA SG 11201501634V A SG11201501634V A SG 11201501634VA
- Authority
- SG
- Singapore
- Prior art keywords
- memory performance
- improving memory
- nootropic
- compositions
- nootropic compositions
- Prior art date
Links
- 230000007334 memory performance Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000001777 nootropic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261696961P | 2012-09-05 | 2012-09-05 | |
EP12306062.6A EP2705841A1 (en) | 2012-09-05 | 2012-09-05 | Combinations of nootropic agents for treating cognitive dysfunctions |
PCT/EP2013/068302 WO2014037412A1 (en) | 2012-09-05 | 2013-09-04 | Nootropic compositions for improving memory performance |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201501634VA true SG11201501634VA (en) | 2015-04-29 |
Family
ID=46963635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201501634VA SG11201501634VA (en) | 2012-09-05 | 2013-09-04 | Nootropic compositions for improving memory performance |
Country Status (17)
Country | Link |
---|---|
US (2) | US9789098B2 (en) |
EP (3) | EP2705841A1 (en) |
JP (1) | JP6228212B2 (en) |
KR (1) | KR20150067168A (en) |
CN (2) | CN104884053B (en) |
AU (1) | AU2013311735B2 (en) |
BR (1) | BR112015004843A2 (en) |
CA (2) | CA2883691C (en) |
EA (1) | EA030385B1 (en) |
ES (2) | ES2709874T3 (en) |
HK (1) | HK1211865A1 (en) |
IL (1) | IL237438A0 (en) |
MX (1) | MX2015002796A (en) |
NZ (1) | NZ705917A (en) |
SG (1) | SG11201501634VA (en) |
WO (1) | WO2014037412A1 (en) |
ZA (1) | ZA201501812B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9682073B2 (en) | 2011-05-19 | 2017-06-20 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder gait and limb impairments treatment |
EA201691602A1 (en) | 2014-02-11 | 2017-03-31 | Фарнекст | COMBINATION OF BACLOPHENE, ACAMPROSATE AND MEDIUM-NECK TRIGGYCERIDES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
CN108025003B (en) * | 2015-07-08 | 2021-07-13 | 基尔罗斯制药有限公司 | Treatment of prefrontal cortical disorders, gait and limb disorders |
US10603297B2 (en) * | 2017-10-04 | 2020-03-31 | Harald Murck | Treatment for therapy refractory depression |
US20210236445A1 (en) * | 2018-01-29 | 2021-08-05 | Pharnext | Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy |
GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
EP4281056A1 (en) * | 2021-01-20 | 2023-11-29 | Alto Neuroscience, Inc. | Combination drug strategy for the treatment of psychiatric and neurological disorders in which anhedonia or motivation- related dysfunction exists |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1485082A4 (en) | 2002-02-19 | 2009-12-30 | Xenoport Inc | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
BRPI0413756A (en) | 2003-08-20 | 2006-10-31 | Xenoport Inc | compound, methods for treating or preventing spasticity or a symptom of spasticity, gastro-oesophageal reflux disease, drug addiction, alcohol addiction or abuse, or nicotine abuse or addiction, and cough or emesis in a patient, and, pharmaceutical composition |
WO2005066122A2 (en) | 2003-12-30 | 2005-07-21 | Xenoport, Inc. | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
ATE511392T1 (en) | 2007-01-11 | 2011-06-15 | Xenoport Inc | DELAYED-RELEASE ORAL DOSAGE FORMS OF A PRODRUG OF R-BACLOFEN AND METHODS OF TREATMENT THEREOF |
US20090082464A1 (en) | 2007-09-07 | 2009-03-26 | Bernd Jandeleit | Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
WO2009033069A1 (en) | 2007-09-07 | 2009-03-12 | Xenoport, Inc. | Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
US20090099253A1 (en) | 2007-10-15 | 2009-04-16 | Xenoport, Inc. | Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use |
US20090118365A1 (en) | 2007-11-06 | 2009-05-07 | Xenoport, Inc | Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain |
WO2009070583A1 (en) * | 2007-11-30 | 2009-06-04 | Wyeth | Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10 |
US20100137442A2 (en) | 2008-02-01 | 2010-06-03 | Xenoport, Inc. | Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment |
WO2009096985A1 (en) | 2008-02-01 | 2009-08-06 | Xenoport, Inc. | Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment |
CA2722295C (en) * | 2008-04-29 | 2019-01-15 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
EA021731B1 (en) * | 2008-04-29 | 2015-08-31 | Фарнекст | Novel compositions for treating alzheimer's disease |
US10071068B2 (en) | 2009-03-03 | 2018-09-11 | Xenoport, Inc. | Sustained release oral dosage forms of an R-baclofen prodrug |
WO2010120370A2 (en) | 2009-04-17 | 2010-10-21 | Xenoport, Inc. | Gamma-amino-butyric acid derivatives as gabab receptor ligands |
TW201111383A (en) * | 2009-05-29 | 2011-04-01 | Wyeth Llc | Substituted imidazo[1,5-a]quinoxalines as inhibitors of phosphodiesterase 10 |
EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
WO2011150380A1 (en) * | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
US20120016021A1 (en) * | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
UA115968C2 (en) * | 2011-03-01 | 2018-01-25 | Фарнекст | NEW COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES |
LT2796132T (en) * | 2011-03-01 | 2018-10-10 | Pharnext | Baclofen and acamprosate based therapy of neurological disorders |
EP2705842A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating parkinson's disease |
-
2012
- 2012-09-05 EP EP12306062.6A patent/EP2705841A1/en not_active Withdrawn
-
2013
- 2013-09-04 MX MX2015002796A patent/MX2015002796A/en unknown
- 2013-09-04 BR BR112015004843A patent/BR112015004843A2/en not_active Application Discontinuation
- 2013-09-04 WO PCT/EP2013/068302 patent/WO2014037412A1/en active Application Filing
- 2013-09-04 EA EA201500294A patent/EA030385B1/en not_active IP Right Cessation
- 2013-09-04 CA CA2883691A patent/CA2883691C/en active Active
- 2013-09-04 JP JP2015530379A patent/JP6228212B2/en active Active
- 2013-09-04 ES ES13759490T patent/ES2709874T3/en active Active
- 2013-09-04 CN CN201380052487.1A patent/CN104884053B/en not_active Expired - Fee Related
- 2013-09-04 NZ NZ705917A patent/NZ705917A/en not_active IP Right Cessation
- 2013-09-04 EP EP13759490.9A patent/EP2892519B1/en active Active
- 2013-09-04 AU AU2013311735A patent/AU2013311735B2/en not_active Ceased
- 2013-09-04 ES ES18196160T patent/ES2886873T3/en active Active
- 2013-09-04 SG SG11201501634VA patent/SG11201501634VA/en unknown
- 2013-09-04 EP EP18196160.8A patent/EP3443955B1/en active Active
- 2013-09-04 US US14/425,987 patent/US9789098B2/en active Active
- 2013-09-04 KR KR1020157008675A patent/KR20150067168A/en not_active Application Discontinuation
- 2013-09-04 CN CN201810311698.7A patent/CN108578396A/en active Pending
- 2013-09-04 CA CA3092974A patent/CA3092974A1/en not_active Abandoned
-
2015
- 2015-02-26 IL IL237438A patent/IL237438A0/en unknown
- 2015-03-17 ZA ZA2015/01812A patent/ZA201501812B/en unknown
- 2015-12-31 HK HK15112901.6A patent/HK1211865A1/en unknown
-
2017
- 2017-10-13 US US15/783,380 patent/US10265304B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2015002796A (en) | 2015-08-20 |
BR112015004843A2 (en) | 2017-07-04 |
EA201500294A1 (en) | 2015-09-30 |
WO2014037412A1 (en) | 2014-03-13 |
EP2705841A1 (en) | 2014-03-12 |
CA2883691C (en) | 2020-11-10 |
CN108578396A (en) | 2018-09-28 |
EP2892519A1 (en) | 2015-07-15 |
ZA201501812B (en) | 2016-07-27 |
US9789098B2 (en) | 2017-10-17 |
US10265304B2 (en) | 2019-04-23 |
KR20150067168A (en) | 2015-06-17 |
IL237438A0 (en) | 2015-04-30 |
NZ705917A (en) | 2018-02-23 |
ES2886873T3 (en) | 2021-12-21 |
EA030385B1 (en) | 2018-07-31 |
US20180092890A1 (en) | 2018-04-05 |
AU2013311735B2 (en) | 2018-02-01 |
CN104884053A (en) | 2015-09-02 |
CA2883691A1 (en) | 2014-03-13 |
CA3092974A1 (en) | 2014-03-13 |
ES2709874T3 (en) | 2019-04-22 |
EP3443955B1 (en) | 2021-06-16 |
CN104884053B (en) | 2018-05-04 |
EP2892519B1 (en) | 2018-11-07 |
HK1211865A1 (en) | 2016-06-03 |
EP3443955A1 (en) | 2019-02-20 |
JP2015527380A (en) | 2015-09-17 |
JP6228212B2 (en) | 2017-11-08 |
US20150224092A1 (en) | 2015-08-13 |
AU2013311735A1 (en) | 2015-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1210019A1 (en) | Chitosan-derived compositions | |
HK1211865A1 (en) | Nootropic compositions for improving memory performance | |
HK1215165A1 (en) | Compositions | |
HK1208354A1 (en) | Compositions | |
EP2763756A4 (en) | Bromofluorocarbon compositions | |
GB201210800D0 (en) | Compositions | |
GB201209244D0 (en) | Compositions | |
GB201201287D0 (en) | Compositions | |
ZA201503157B (en) | Compositions | |
GB201103942D0 (en) | Compositions | |
ZA201503062B (en) | Compositions | |
GB201220068D0 (en) | Compositions | |
ZA201406753B (en) | Long acting compositions | |
ZA201502542B (en) | Compositions | |
GB201219980D0 (en) | Compositions | |
GB201219973D0 (en) | Compositions | |
GB201219962D0 (en) | Compositions | |
TWI561248B (en) | Peracid-generating compositions | |
EP2926813A4 (en) | Metformin-orlistat compositions | |
GB201223148D0 (en) | Compositions | |
GB201222702D0 (en) | Compositions | |
GB201218959D0 (en) | Compositions | |
GB201209189D0 (en) | Compositions | |
GB201209187D0 (en) | Compositions | |
GB201204103D0 (en) | Compositions |